ClinicalTrialsFinder
RecruitingNCT05934864

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST Study)

Sponsor

Ruijin Hospital

Enrollment

1,000 participants

Start Date

Jul 13, 2023

Study Type

OBSERVATIONAL

Conditions

Peripheral T Cell Lymphoma

Summary

A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology from June 2023 to December 2026 and detected by gene sequencing (NGS) with different molecular subtypes.
  • Patients diagnosed with PTCL by histopathology from January 2023 to June 2023 and NGS detection can be performed if there is tumor tissue.
  • Informed consented
  • Age ≥ 18 years

Exclusion Criteria5

  • History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior to study treatment
  • Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease
  • Not able to comply to the protocol for mental or other unknown reasons
  • Patients with mentally disorders or other reasons unable to fully comply with the study protocol
  • Pregnant or lactation

Interventions

GENETIC84-gene penal

84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.

Locations(6)

Peking University People's Hospital

Beijing, China

Henan Cancer Hospital

Henan, China

Affiliated Drum Tower Hospital, Medical School of Nanjing University

Nanjing, China

Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

Shandong, China

Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, China

Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05934864

Related Trials

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT065084632 locations

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

NCT074709961 location

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

NCT074147581 location

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

NCT070554771 location

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT061318015 locations